Food Allergy Market Poised to Reach USD 58.86 Billion by 2031 as Diagnostics and Digital Allergy Management Expand

The global food allergy market is projected to expand from USD 39.99 billion in 2024 to USD 58.86 billion by 2031, registering a CAGR of 5.68% over the forecast period, as rising global prevalence, heightened consumer awareness, and rapid innovation in diagnostics and treatment reshape how the condition is identified and managed. The market’s growth trajectory underscores a broader public health shift: food allergies are no longer viewed as a niche pediatric concern but as a widespread, cross-generational condition demanding sophisticated clinical and consumer-facing solutions.

A food allergy occurs when the immune system mistakenly identifies specific food proteins as harmful, triggering reactions that range from mild discomfort to life-threatening anaphylaxis. The market encompasses the full ecosystem built around this condition — diagnostic tests such as skin prick tests and specific IgE blood panels, treatment options including antihistamines, corticosteroids and immunotherapy, and a growing array of allergen-free food products designed to help affected individuals manage daily life safely.

Antihistamines Remain the Treatment Backbone

Among treatment categories, antihistamines generated the highest revenue in 2023 at USD 15.55 billion, reflecting their continued role as the frontline response to allergic reactions. The segment benefits from a dual-generation product structure: first-generation antihistamines such as diphenhydramine offer fast relief but often induce sedation, while second-generation options like loratadine and cetirizine provide non-sedating relief suited to long-term use. The availability of both over-the-counter and prescription formulations allows the segment to serve a wide spectrum of allergy severity and patient preference, reinforcing its market leadership.

Peanuts Dominate the Allergen Landscape

Segmented by food source — tree nuts, dairy, wheat, soy, peanuts, poultry, and shellfish, among others — peanuts captured the largest share at 19.73% in 2023. Peanut allergies remain among the most common and potentially severe food allergies globally, driving stringent safety practices across food production and retail. This has translated into surging demand for allergen labeling, with consumers actively seeking peanut-free certification and manufacturers investing in dedicated production lines and rigorous cross-contamination controls to meet that demand.

Homecare Emerges as the Fastest-Expanding End-User Segment

The homecare segment is projected to become the highest-revenue end-user category, reaching USD 23.5 billion by 2031. This growth reflects a broader shift toward allergen avoidance and symptom management taking place within the home rather than solely in clinical settings. Homecare solutions span allergen-free food substitutes for peanuts, dairy, eggs, and gluten, alongside home allergen testing kits that let individuals identify triggers in their own environment.

Digital tools are reinforcing this shift. Allergy management apps and online support communities are increasingly central to how patients educate themselves and monitor their conditions day to day, supporting the broader move toward convenience, safety, and autonomy in allergy management.

Global Cuisine Trends Widen Allergen Exposure

An unexpected but significant trend fueling market growth is the global expansion of international cuisine. As dishes rooted in specific culinary traditions gain popularity far beyond their countries of origin, consumers are increasingly exposed to unfamiliar ingredient combinations — and, by extension, unfamiliar allergen risks. This growing cross-cultural culinary exchange has heightened the need for accurate allergen information at restaurants and specialty food outlets alike, adding a new dimension to allergy risk management.

Telemedicine and Mobile Apps Reshape Allergy Care Delivery

The proliferation of telemedicine and mobile health applications is fundamentally altering how allergy care is delivered. Platforms offering real-time environmental allergen data and personalized dietary management tools are empowering patients to take a more active role in managing their condition. Meanwhile, telemedicine services are extending specialist access across geographic boundaries, enabling remote consultations and follow-up care that reduce the friction traditionally associated with allergy management. Together, these technologies are driving a broader shift toward proactive, patient-centered care models.

Cost of Diagnosis Remains a Persistent Barrier

Despite strong momentum, the high cost associated with food allergy testing and diagnosis continues to pose a challenge to market development. The often-iterative nature of allergy diagnosis can prolong the path to a definitive answer, leading to unnecessary tests, repeated consultations, and rising healthcare costs for patients. Even so, the rapid evolution of new treatment technologies — including biologic therapies such as Omalizumab, which has shown promise in reducing anaphylactic reactions during oral immunotherapy — signals a maturing therapeutic landscape that could ease this burden over time.

Regional Outlook: Asia-Pacific Leads, North America Advances Steadily

Asia-Pacific held the largest regional share in 2023 at 35.66% (USD 13.69 billion), driven by high population density, shifting dietary patterns, and expanding healthcare infrastructure investment. Rapid urbanization across the region is increasing consumption of processed foods, a dynamic directly linked to the rising incidence of food allergies, particularly in urban centers.

North America is expected to post steady growth at a CAGR of 4.22%, supported by advanced healthcare infrastructure, strong labeling regulations, and intensifying competition among diagnostic and treatment providers seeking to improve access to allergy management solutions.

Competitive Landscape

The market remains fragmented, with companies such as Alletess Medical Laboratory, ALS Limited, Asurequality Ltd, Charm Sciences, Crystal Chem Inc., Intertek Group plc, Mérieux NutriSciences Corporation, Microbac Laboratories, Eurofins Scientific, and Neogen Corporation competing through partnerships, product innovation, and expanded testing capabilities. A notable development came in March 2024, when Gold Standard Diagnostics launched the SENSIStrip Gluten PowerLine Lateral Flow Device, a highly sensitive monoclonal-antibody-based test capable of detecting gluten residues across food matrices, rinse water, and swabs — illustrating the continued push toward faster, more precise allergen detection tools.

Outlook

As awareness continues to rise alongside regulatory pressure for stringent food safety and labeling standards, the food allergy market is set for sustained expansion through 2031. The convergence of advanced diagnostics, biologic therapeutics, and digital health tools suggests the sector is moving toward a more integrated, patient-centric model of allergy care — one capable of supporting the millions of individuals worldwide navigating food allergies daily.